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MS-based proteomic methods were utilised for the ﬁrst time in the discovery of novel penile
cancer biomarkers. MALDI MS imaging was used to obtain the in situ biomolecular MS proﬁle
of  squamous cell carcinoma of the penis which was then compared to benign epithelial
MS  proﬁles. Spectra from cancerous and benign tissue areas were examined to identify
MS peaks that best distinguished normal epithelial cells from invasive squamous epithelial
cells, providing crucial evidence to suggest S100A4 to be differentially expressed. Veriﬁcation
by  immunohistochemistry resulted in positive staining for S100A4 in a sub-population ofeywords:
ALDI MS imaging
enile cancer
100A4
invasive but not benign epithelial cells.
©  2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).iomarker discovery
.  Introduction
enile cancer is a rare cancer in developed countries with
pproximately 500 cases diagnosed each year in the UK [1].
here is an increased incidence of penile cancer in South
merica and Western Africa, which has been putatively
xplained by the socioeconomic conditions and restricted
ccess to health care in these countries [2]. Squamous cell
∗ Corresponding author at: Department of Chemistry, University of Rea
E-mail  address: r.k.cramer@reading.ac.uk (R. Cramer).
ttp://dx.doi.org/10.1016/j.euprot.2015.02.001
212-9685/© 2015 The Authors. Published by Elsevier B.V. on behalf of
rticle  under the CC BY license (http://creativecommons.org/licenses/bcarcinoma (SCC) is the most common subtype of penile
cancer accounting for ∼95% of new cases each year [3].
Other malignant tumour types include adenocarcinoma, lym-
phoma, melanoma, and various mesenchymal tumours such
as Kaposi’s sarcoma and leiomyosarcoma [4]. Premalignantding, Whiteknights, Reading RG6 6AD, UK. Tel.: +44 1183784550.
conditions eponymously termed Bowen’s disease, Erythropla-
sia de Queyrat and Bowenoid papulosis represent carcinoma
in situ or penile intra-epithelial neoplasia (PeIN 3). These can
develop into invasive SCC if left untreated [2]. The primary
 European Proteomics Association (EuPA). This is an open access
y/4.0/).
 o m i c2  e u  p a o p e n p r o t e
treatment for penile cancer has moved to more  conservative
penile preserving techniques in order to maintain function.
These include glansectomy and reconstruction and glans
resurfacing procedures which have a good cosmetic and
functional outcome compared to radical surgery. [5]. The lym-
phatic dissemination of penile cancer occurs in a predictable
step-wise fashion; ﬁrstly to the inguinal nodes and subse-
quently to the pelvic nodes and then the para-aortic nodes
[6]. Clinically the best prognostic indicator is the presence of
metastatic inguinal lymph nodes [7]. However, despite a num-
ber of potential molecular biomarkers and the development of
nomograms, there is as yet no reproducible biomarker avail-
able which is a reliable indicator for prognosis and metastatic
potential in the primary tumour [8].
In the 1990s, matrix-assisted laser desorption/ionisation
(MALDI) mass spectrometry imaging (MSI) was established
[9,10]. MALDI MSI  can be employed for the simultaneous
in situ visualisation and spatial mapping of various classes of
molecules, from drug metabolites [11] to large proteins [12,13].
The ability to detect signals in their native environment gives
information on local production of biomolecules as well as
their distribution across different disease states of the tissue.
This information can be lost if a large-scale tissue digestion
protocol is followed, such as in the more  traditional bottom-up
proteomics approach.
MALDI MSI  provides an excellent platform upon which
molecular pathology can be applied, giving the investiga-
tor a “ﬁrst-view” of the global biomolecular proﬁle of the
tissue and the various micro-environments present [14]. It
has successfully been applied to a number of cancers [15,16]
to provide the basis for more  targeted analysis either via
the traditional immunohistochemistry route or more  sophis-
ticated shotgun-type mass spectrometry methods. In this
study, we  present MALDI MSI  results showing differentially
expressed biomolecules in penile cancer tissue. This initial
primer experiment served as an excellent starting point to
study the malignancy in its anatomical context. Furthermore,
the immunoactivity of S100A4 protein in penile cancer tumour
tissue was measured and its correlation to the clinical grading
of the tumour was determined. From these measurements,
it can be concluded that a sub-population of S100A4-positive
epithelial cells exists in the tumour environment and is virtu-
ally absent in matched benign tissue.
2.  Materials  and  methods
2.1.  Sample  collection
Fresh tissue specimens, superﬂuous to that required for diag-
nostic evaluation, were collected from patients undergoing
surgery for the removal or biopsy of penile cancer at the
Department of Urology, Royal Berkshire Hospital, Reading, UK.
Formalin-ﬁxed parafﬁn-embedded (FFPE) penile tissue was
collected for immunohistochemistry at the Department of
Urology, University College London Hospital, London, UK. All
specimens were procured with the approval from the Uni-
versity of Reading and Berkshire Research Ethics committees
(10/H0505/16) and full informed consent was granted by the
participants. s 7 ( 2 0 1 5 ) 1–10
2.2.  Tissue  preparation  and  matrix  application  for
MALDI  MSI
Two consecutive tissue slices with a thickness of 10 m and
5 m were cut from two different frozen tissue blocks (T1 and
T2) from two different patients and labelled T1-10, T1-5, T2-10
and T2-5. The area of the T1-10 was approx. 16.5 mm × 15 mm
and for T2-10 this was approx. 16.5 mm × 9.5 mm.  A Leica
CM3050 S cryostat microtome (Leica Biosystems, Peterbor-
ough, UK) was used to cut the slices from the fresh frozen
tissue blocks, which were then thaw-mounted on ground steel
MALDI target plates (Bruker Daltonics, Bremen, Germany) at
−20 ◦C. The tissue slices were brought to room temperature
under vacuum for 30 min. Tissue ﬁxation and removal of
salts and excess haemoglobin were done through a series
of ethanol/water wash steps as described by Schwartz et al.
[17]. Subsequently, the tissue slices were dried under vacuum
for another 10 min. A matrix solution with a concentra-
tion of 10 mg/ml  was made of sinapinic acid (Sigma–Aldrich
Co. Ltd., Gillingham, UK) dissolved in a 60:39.8:0.2 solu-
tion of acetonitrile:water:triﬂuoroacetic acid, which were
all MALDI grade reagents from Sigma–Aldrich. The tissue
slices were spray-coated with the matrix solution using a
TLC sprayer (Sigma–Aldrich) at an optimised distance of
30 cm.  At this distance it was found that a light matrix
coat was applied evenly and reproducibly across the slices.
After spraying the tissue, it was allowed to dry for 5 min,
before repeating the cycle. This process was repeated ﬁve
times ensuring an even deposition of matrix was observed
across the slice. A calibration spot consisting of a stan-
dard solution of proteins and peptides (Bruker Daltonics) was
added beside the mounted tissue slice for calibration pur-
poses.
2.3.  MS  analysis  and  data  processing
Mass spectra were acquired over an m/z range of 2,000–18,000
in positive linear mode and a laser repetition rate of
50 Hz using an Ultraﬂex MALDI axial-TOF mass spectrometer
(Bruker Daltonics) with the acquisition software FlexCon-
trol 3.0. Custom geometry ﬁles were created to specify
the imaging area using the in-house software PIMSS [18].
Using AutoExecute in FlexControl, MS images were recorded
with a 200-m spatial resolution, averaging the data from
50 shots per image  pixel. PIMSS was used to convert raw
data ﬁles into Analyze 7.5 format for image  visualisation in
BioMap (Novartis, Basel, Switzerland; http://www.maldi-msi.
org).
For further data analysis, a representative population of
spectra from areas of different tissue pathology (70 spectra
from each region of interest) were extracted from the data
set of the T1-10 tissue slice. On these spectra, classiﬁcation
and statistical evaluation was performed using ClinProTools
2.1 (Bruker Daltonics). The spectra were ﬁrst processed and
peaks were detected using a signal-to-noise cut-off of 5. The
peak intensity values used for subsequent analysis were based
on peak height. A Mann–Whitney U test was used for pair-wise
comparison of peak intensities from normal and cancerous
regions.
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.4.  H&E  and  S100A4  immunohistochemistry  staining
.4.1.  Haematoxylin  and  eosin  staining
 5-m-thick consecutive tissue slice of a slice that was
sed for MSI  was mounted on a glass slide, immersed in
eutral buffered formalin for 45 s and rinsed under running
ap water. It was then put into a Harris haematoxylin solu-
ion for 1 min, followed by a second rinse under running
ater. The slice was brieﬂy dipped into 0.5% acidic alcohol
or 15 s, rinsed under running tap water and then placed in
he bluing reagent sodium bicarbonate for 15 s. To complete
he staining the slice was counterstained in Eosin Yellow-
sh for 30 s and taken through increasing concentrations of
lcohol (75/90/100%) before being immersed in the clearing
gent Xylene (Genta Medical, Tockwith, UK). The stained and
xed slice had a coverslip placed over it using the mounting
edium Pertex (Leica Biosystems, Newcastle Upon Tyne, UK)..4.2.  Antibody  optimisation  and  immunohistochemistry
he rabbit polyclonal anti-S100A4 antibody (A5114; Dako, Ely,
K) was chosen for use in this study due to its reported high
ig. 1 – (A) and (B) show the H&E-stained T1-5 and T2-5 penile ti
y the histopathologist. The distribution of the m/z  11,637 ion ac
SI data set, is given in (C) and (D). Panels (E) and (F) show an ov
n top of the H&E images. s 7 ( 2 0 1 5 ) 1–10 3
speciﬁcity for S100A4 and suitability for use with formalin-
ﬁxed parafﬁn-embedded (FFPE) tissues. Several 3-m-thick
sections of an in-house research tissue microarray (TMA)
block containing a variety of normal and neoplastic tissues
were used for antibody optimisation on the Bond-III auto-
mated staining platform (Leica Biosystems, Newcastle Upon
Tyne, UK). The sections underwent automated dewaxing,
and endogenous peroxidase was blocked using 3–4% (v/v)
hydrogen peroxide. The antibody was tested with a range of
citrate-based (pH 6.0) and EDTA-based (pH 9.0) heat-induced
epitope retrieval methods. Dilution curves for anti-S100A4
were carried out (1/100, 1/200, 1/500, 1/1000, 1/1500, 1/2000 and
1/3000) with 15 min  incubation at ambient temperature. The
signal was visualised using the Bond Polymer Reﬁne Detection
kit (DS9800) with DAB Enhancer (AR9432) and haematoxylin
counterstain. The sections were reviewed and optimal con-
ditions chosen based upon the criterion of background-free
selective cellular labelling. The antibody was taken forward
for use on 20 penile cancer cases at a dilution of 1/1000 with
heat-induced epitope retrieval using a citrate-based (pH 6.0)
retrieval solution for 20 min.
ssue slices with the regions of interest marked as identiﬁed
ross both the T1-10 and T2-10 slices, as obtained from the
erlay of the highest signal intensity from the MSI  images
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2.4.3.  Histopathological  evaluation  and  analysis  of
S100A4  tissue  staining
All immunostained sections were examined by the same
histopathologist using light microscopy. The clinical grading
or diagnostic information for each case was not revealed to
the histopathologist prior to this examination. The staining
pattern of the S100A4-positive epithelial cells in the invasive
tumour area was compared with that of the normal epithe-
lial area in the same section. The staining within the invasive
tumour areas was further examined by counting the number
of positive-stained epithelial cells using high-power ﬁeld (HPF)
view (400× magniﬁcation) and taking care to avoid counting
dendritic cells which also stained positive for S100A4. The area
with the maximum number of S100A4-positive epithelial cells
was thus located using low magniﬁcation and scanning the
invasive region to identify the area where the highest num-
ber of positive cells was located. The staining pattern was
classiﬁed as follows: ﬁve or less S100A4-positive cells in one
HPF view as slightly positive (+), between six and nineteen
S100A4-positive cells in one HPF view as positive (++), and
ﬁnally twenty or more  S100A4-positive epithelium cells in one
HPF view as markedly positive (+++) [19]. A Chi square test was
used to assess the correlation between the number of positive
cells and the clinical grading of the cancer. For all statistical
tests the level of signiﬁcance was set at 0.05. One of the stained
tissue slices, which only had carcinoma in situ was excluded
from further evaluation.
3.  Results
The 10 m slices T1-10 and T2-10 were analysed by MALDI
MSI, creating ion distribution maps with a lateral resolu-
tion of 200 m,  whilst the 5-m-thick slices T1-5 and T2-5
were stained using a traditional haematoxylin and eosin
(H&E) stain. The H&E staining patterns were examined by a
histopathologist using light microscopy, and regions of benign
and malignant squamous cell epithelium were marked on
both T1-5 and T2-5 (see Fig. 1(A) and (B)). The tumour grade in
both T1 and T2 was identiﬁed as Grade 2 (moderately differ-
entiated) squamous cell carcinoma.
In T1-5, the histopathologist marked three distinct regions
– invasive squamous epithelial cell carcinoma, Lichen Sclero-
sus (BXO) and hyperplastic epithelial cells (normal). Based on
this report, regions of interest representing normal and can-
cerous areas were selected and spectra from both of these
regions of T1-10 were exported to the ClinProTools software
for peak identiﬁcation and statistical analysis. After initial
processing (baseline subtraction and smoothing) and normal-
isation against each slice’s total ion current (TIC) value, a total
of 107 individual peaks were identiﬁed across the two regions.
Fig. 2 illustrates the average spectra from the cancer (A) and
normal (B) region as obtained from ClinProTools analysis. The
average intensity of each peak in the normal region and the
cancerous region was compared using the Mann–Whitney U
test (also known as Wilcoxon rank-sum test). Table 1 details
the 10 most signiﬁcantly different peaks between the two
regions. The peak intensity at m/z 11,637 ± 2 was found to
be signiﬁcantly higher in the cancerous region of the tissue
slice (p < 0.05). Using the software BioMap, the distribution of
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Fig. 2 – MALDI MS  average spectra from normal (A) and cancer (B) epithelial cell regions of the T1-10 slice from tissue block
T1. The spectra were all processed as described in Section 2, and the signal intensities at each m/z were  compared to
i  mos
b
t
w
i
(
s
a
i
t
t
e
m
i
N
k
o
w
S
s
i
t
4
a
i
l
e
n
t
e
w
t
cell. Table 2 details the results from the positive cell count-
ing immunostaining experiment with the S100A4 antibody. A
signiﬁcant correlation was found (p = 0.017) using a Chi square
test between the increasing number of positive S100A4 cells
Fig. 3 – A high power ﬁeld (HPF) view (400×) of an area ofdentify signiﬁcant difference between the two regions. The
oth spectra with an asterisk.
he m/z 11,637 ion across the tissue in both T1-10 and T2-10
as visualised. The images in Fig. 1(C) and (D) show the signal
ntensity distribution of this ion and the images in Fig. 1(E) and
F) give an overlay of its signal intensity onto the H&E-stained
lices. Supplementary Fig. 1 shows the distribution of m/z 4964
cross the entire tissue section, showing that for some m/z the
on distribution was spread across both malignant and benign
issue sections whilst being conﬁned to the tissue section only.
Supplementary Fig. 1 related to this article can be found, in
he online version, at doi:10.1016/j.euprot.2015.02.001.
A peak at m/z  11,639 ± 2 was previously identiﬁed in the lit-
rature as S100 calcium-binding protein A4 (S100A4) [20]. The
olecular weight of S100A4 in the UniProt human database
s 11,729 Da. Taking into consideration that S100A4 loses its
-terminal methionine (-131 Da) upon activation and is also
nown to undergo acetylation (+42 Da), the expected m/z value
f the singly charged S100A4 would be 11,641. The decision
as taken to further investigate the potential association of
100A4 in penile carcinoma as it was found to have the most
igniﬁcant signal difference across the tissue sections. The
dentity of other biomolecular entities in Table 1 was inves-
igated in a similar way as that for S100A4. The peak at m/z
932.6 could be putatively identiﬁed as Thymosin Beta 10 [21],
 protein that has previously been found to be over-expressed
n a number of cancers including thyroid and hepatocellu-
ar carcinoma [22,23]. To identify the underlying biomolecular
ntity for the remainder of the peaks in Table 1, one would
eed to undertake a more  detailed on-tissue bottom-up pro-
eomics approach.Thus, 20 tissue slices from formalin-ﬁxed parafﬁn-
mbedded (FFPE) penile tissue blocks were immunostained
ith an S100A4 antibody. The immunostaining showed that
here was no expression of S100A4 in normal epithelial cells ort signiﬁcantly different peak at m/z 11,637 is marked in
areas of lichen sclerosis. However, in the proliferating tumour
regions small sub-populations of S100A4-positive cells were
detected. In order to assess only epithelial cells, care had to be
taken within the tumour region to distinguish between epithe-
lial and dendritic cells, as the S100A4 antibody labelled both
cell types (see Fig. 3). Dendritic cells differ from epithelial cells
in morphology, possessing long cytoplasmic arms (dendrites)
that extend from the nucleus, whereas epithelium cells are
typically rounder. Where there was any uncertainty in the
cell type, the cell in question was not counted as a positiveS100A4 antibody-stained tissue with both positive
dendritic and epithelial cells marked. The different
morphological features of the two cell types are clearly
visible (see text for details).
6  e u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 1–10
Table 2 – Results of the S100A4 immunohistochemical of the penile cancer specimens along with metadata for each
sample.
Sample number No. of positive S100A4 cells Pathology grade Stagea Lymph nodea
1 3 1 PT1 N0
2 4 2 PT2 N0
3 5 3 PT3 N0
4 6 2 PT1 N0
5 7 2 PT1 N0
6 11 2 PT1 N0
7 11 2 PT2 N2
8 11 2 PT2 N0
9 17 3 PT2 N0
10 20 2 PT1 N0
11 20 2 PT2 N0
12 20 3 PT1 N0
13 20 3 PT2 N0
14 20 3 PT2 N2
15 20 3 PT2 N0
16 20 3 PT2 N0
17 20 3 PT3 N2
18 20 3 PT3 N3
19 20 3 PT3 N0
b
ent th20 17
a PT1–PT3 represent the primary tumour stages whilst N0–N3 repres
b This sample is the lymph node tissue from sample no. 17.counted in the invasive region of the tissue and the clinical
grade of the removed tumour (as taken from the pathology
report). Fig. 4 shows that 80% of the pathology Grade 3 tumours
were markedly positive for S100A4. Only two out of the 10
Fig. 4 – S100A4 expression in invasive penile squamous cell carc
with ﬁve or less S100A4-positive epithelial cells. (B) Positive (++) 
S100A4-positive epithelial cells. (C) Markedly positive (+++) S100
epithelial cells. All images were  taken at 200× magniﬁcation. Th
in the three categories for S100A4 positive staining.e nodal tumour stages, using the TNM staging system.Grade 3 tumours were found to have less than 20 positive
cells per HPF. Although there was only one Grade 1 tumour
in the sample cohort, it was only slightly positive for S100A4.
Importantly, the results show that the majority of the Grade
inoma. (A) Slightly positive (+) S100A4 immunoactivity
S100A4 immunoactivity with between six and nineteen
A4 immunoactivity with twenty or more  S100A4-positive
e graph in (D) shows the percentage of each clinical grade
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 tumours could be separated from the Grade 3 tumours by
xamining the immunoreactivity of S100A4 in the invasive
egions (Fig. 4(D)).
For one of the participants both a primary tumour and a
etastatic lymph node sample were provided. In this case,
100A4-positive epithelial cells were also observed to be
resent in the invasive islands of the lymph node metastasis
n addition to those found in the primary tumour.
.  Discussion
SI  experiments can generate data ﬁles well in excess of
 Gb per image  depending on the mass range, pixel size and
mage size. This data set enables the user to view the dis-
ribution of any ions measured across the tissue surface.
dvantages of MSI  experiments include the small amount of
ample that is consumed in a single analysis and the ability
o directly compare the ion distribution map  with histol-
gy results from a consecutive tissue slice [24]. MALDI MSI
xperiments have proven very successful at identiﬁcation of
otential biomarkers, even when small cohorts are used in
he initial experiments. In this case study we directly com-
ared ion distribution maps created from two separate penile
issue blocks removed during surgery for penile carcinoma
ith consecutive H&E-stained slices to investigate the local-
sation of speciﬁc ion signals in areas of different pathology,
.e. tumour regions versus regions of similar cellular origin
hat show no sign of malignancy (benign/normal epithelial
ells).
Due to the large number of data points that were col-
ected during the imaging experiments, it would have been
abour- and time-consuming, along with an increased risk of
issing signiﬁcant results, to scroll through each ion distri-
ution map  and evaluate if there was differential expression
n speciﬁc regions of the tissue. By taking the representa-
ive spectra from sufﬁciently large areas of the tumour and
ormal region, constructing an averaged peak list and sub-
ecting it to comparative analysis it allowed the identiﬁcation
f ion signals that were signiﬁcantly different between the
ifferent pathological regions of the tissue. As the data of
ig. 1(E) and (F) show, the distribution of the ion signal at m/z
1,637 is conﬁned to the invasive epithelial cellular regions,
hereas at other m/z ratios the ion signal distribution is spread
qually across the entire epithelial cellular region of the tissue
lice.
Although we were unable to identify the biomolecule
esponsible for this difference in signal intensity by mass spec-
rometry, despite trying on-tissue enzymatic digestion [25]
nd laser-capture microdissection methods [26,27], the pub-
ished literature suggests that this peak can be attributed
o the protein S100A4. Stoeckli et al. reported in 2001 that
hey identiﬁed a peak at m/z 11,639 ± 3 as S100A4 with an
ncreased signal intensity in glioblastoma tumour regions
rom MSI  experiments [20]. This result is also recorded in
oth bottom-up and top-down experiments in the MaTisse
atabase [28]. Further support for this assignment was found
n the UniProt human database sequence entry, indicating that
he activated form of S100A4 could indeed be the underlying
rotein. s 7 ( 2 0 1 5 ) 1–10 7
Similar to previously published research in various can-
cers, e.g. ovarian [16], colon [15], and gastric cancer [29], MALDI
MSI was used to effectively monitor hundreds of compounds
across the tissue surface in a case-study cohort, and statis-
tical analysis enables the initial ﬁrst-pass identiﬁcation of
the more  discriminating peaks between normal and malig-
nant environments. Based on the identiﬁcation information a
study population of penile tumour tissue slices was investi-
gated by an immunoassay using an S100A4-speciﬁc antibody.
Evaluation of the immunoassay results found that despite the
small sample size there was a signiﬁcant correlation between
the number of S100A4 positive epithelial cells in the inva-
sive tumour and the histopathological grade of the cancer
(p = 0.017).
S100 calcium-binding proteins are small, acidic proteins
(10–12 kDa) and are part of the larger Ca2+-binding EF-hand
motif superfamily [30]. They have a broad range of intra- and
extracellular functions including regulation of protein phos-
phorylation and the modulation of the cytoskeleton dynamics
in metastatic cells [31], and are also involved in calcium
homeostasis and the regulation of transcription factors [32]. It
is known that the over-expression of S100A4 in cells can cause
disruption of p53 phosphorylation [30,33], which can lead to
a decrease in apoptosis and an increase in cell proliferation
and tumour growth. The role of p53 as a possible prognostic
marker, along with its general role in HPV-dependent penile
cancer progression, has been investigated in previously pub-
lished research [34]. It was found by Martins et al. that the
over-expression of p53 was associated with tumour progres-
sion and the cause of speciﬁc cell death [34].
So far only a few penile cancer-speciﬁc candidate markers
have been described. For instance, Campos et al. investigated
E-cadherin levels in penile cancer and found a signiﬁcant cor-
relation between lower expression levels of E-cadherin and an
increased risk of lymph node metastasis [35]. E-cadherin is
one of the most important molecules in cell–cell adhesion in
epithelial tissue, and a decrease in its expression is linked with
metastatic cells that grow and function without the normal
regulated cellular environment [36]. Interestingly, increased
levels of S100A4 have previously been reported to be con-
comitant with reduced levels of E-cadherin in many  different
tumours including non-small cell lung cancer [37], malig-
nant melanoma [38] and oral squamous cell carcinoma [39].
Campos et al. also investigated the matrix metalloproteinases
MMP-2 and MMP-9 and evaluated their potential as prognostic
markers for lymph node metastasis from penile cancer. Matrix
metalloproteinase proteins are a group of zinc enzymes that
are responsible for degradation of extracellular matrix compo-
nents such as collagens and proteoglycans [40]. Campos et al.
found that neither showed any correlation with an increased
risk of lymph node metastasis, but that the level of MMP-9
was an independent risk factor for disease recurrence [35].
These observations are important indicators of the role that
S100A4 plays in the biological progress of penile cancer. The
reduction of adhesion as indicated by the loss of E-cadherin
is one marker for cells undergoing epithelial–mesenchymal
transition (EMT), and S100A4 is known to be a master medi-
ator in EMT [41], whilst S100A4’s interaction with Annexin
II and MMP proteins is thought to promote metastasis
by inducing remodelling of the extracellular matrix and
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as a result to facilitate angiogenesis and tumour invasion
[42,43].
From the immunohistochemical results of the tissue
sections using an S100A4-speciﬁc antibody, the tumour envi-
ronment was shown to have a heterogeneous population of
invading epithelial cells. The immunostaining results were
semi-quantitatively measured and using the results of the sta-
tistical analysis a signiﬁcant correlation between the number
of S100A4-positive cells and the histopathological grade of the
tumour. It has been widely hypothesised recently that this cel-
lular diversity or heterogeneity within the tumour could be
a result of small population of cancer stem cells or cancer-
initiating cells (CICs) [44–47]. If, following further validation,
the ﬁndings were found to hold true and the aggressiveness
of the cancer along with the chances of detecting positive
lymph nodes earlier could be tested through the immunoas-
say staining for presence of S100A4 protein, the assay could
be translated to a more  automated method of staining evalu-
ation, e.g. CMYK.
In the pathologically related head and neck squamous
cell carcinoma, a sub-population of S100A4-positive cells was
observed by Lo et al. [19]. They found that the S100A4 path-
way played a critical role in maintaining the stem-cell like
properties of a sub-population of cells within the tumour
that are proposed to be CICs or cancer stem cells. Another
of their ﬁndings was that the increased signalling of S100A4
within this tumour increased the tumourigenicity of the cells
in question [19]. Similar to this study they reported a signiﬁ-
cant correlation between S100A4 expression and the clinical
grading of the head and neck cancer, and in addition found
a correlation between patient survival and increased levels
of the stemness markers Nanog and Oct-4. Given that these
two squamous cell malignancies are pathologically so closely
related it can be postulated that the expression of S100A4 in
the sub-population of invasive cells in penile cancer plays a
similarly critical role as in head and neck squamous cell car-
cinoma.
Prognosis for penile cancer following removal of the pri-
mary  tumour depends on the lymph node status. If there
are clinically impalpable inguinal lymph nodes (cN0) then
the risk of harbouring occult metastases is approximately
20% [6]. Lymphadenectomy before the nodes become palpable
infers a survival advantage but carries a signiﬁcant morbid-
ity risk and would mean overtreatment of 80% of patients.
Although dynamic sentinel lymph node biopsy has addressed
this in some centres worldwide, the false negative rate is still
7%. Better risk stratiﬁcation could mean fewer lymphadenec-
tomies for men  that do not need them and earlier lymph
node removal for those that do (i.e. prior to them becoming
palpable), thus reducing morbidity and mortality. The results
reported here show that increasing histopathological grades
of penile cancer have higher numbers of S100A4-positive cells
within the invasive islands. Taking into account that the
trial cohort was quite small, the results need to be veriﬁed
using a larger number of participants. To further improve the
detection and evaluation of the staining patterns of S100A4
in malignant tissue, digital pathology could be used (meth-
ods such as CMYK). The early promise shown by S100A4
certainly justiﬁes further investigation into its prognostic
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5.  Conclusion
MALDI MSI  afforded the detection of tumour-associated ions
in the invasive areas of penile cancer tissue slices, demon-
strating the potential of the MSI technique to uncover novel
tumour-speciﬁc markers for penile cancer. The signiﬁcant dif-
ference in the peak signal intensity at m/z  11,637 between the
averaged normal and cancer spectra taken from sufﬁciently
large tissue regions was also reﬂected in the ion distribution
image for this particular m/z value. Using literature and known
protein sequence data, the peak was putatively assigned to the
protein S100A4. S100A4 protein levels were also measured in
a larger sample population by immunohistochemistry and it
was found that there was a signiﬁcant correlation between the
number of positive cells in the tissue and the clinical tumour-
grading. However, to further clarify the prognostic (staging)
power of S100A4 in squamous cell carcinoma of the penis,
additional studies with a larger number of cancer specimens
as well as follow-up studies on survival rates are needed. A
second strand of follow-up analysis will be to investigate the
remaining peaks from Table 1 (including Thymosin Beta 10)
and carry out both an initial immunohistochemistry analysis
to evaluate the biomarker and then to progress both S100A4
and of the other peaks to large-scale clinical validation.
Examining S100A4-speciﬁc staining in the primary tumour
of patients with penile cancer may offer complementary
information that could aid the pathologist in assessing the
aggressiveness of the cancer and increase the chances of
detecting positive lymph nodes earlier and/or without the
need for further biopsies.
Signiﬁcance
Our study demonstrates the application of mass spectrome-
try imaging for the identiﬁcation of molecular species capable
of distinguishing between benign and malignant penile tissue.
In a follow-on study S100A4 was shown to be heterogeneously
distributed in malignant penile tissue. This case study is very
signiﬁcant as research into penile cancer is rare and an ini-
tial study such as the one presented in this manuscript offers
exciting new insights into potential cell differentiation across
malignant tissue in penile cancer.
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